R1 RCM (NASDAQ:RCM) Downgraded to “Hold” at Jefferies Financial Group

Jefferies Financial Group cut shares of R1 RCM (NASDAQ:RCM) from a buy rating to a hold rating in a research note released on Thursday morning, Marketbeat reports.

RCM has been the topic of a number of other research reports. Canaccord Genuity Group reissued a buy rating and issued a $15.00 price target on shares of R1 RCM in a research note on Monday, July 22nd. KeyCorp restated a sector weight rating on shares of R1 RCM in a research report on Wednesday, April 10th. Royal Bank of Canada restated an outperform rating and issued a $19.00 price objective on shares of R1 RCM in a research report on Friday, June 28th. Cantor Fitzgerald restated an overweight rating and issued a $20.00 price objective on shares of R1 RCM in a research report on Tuesday, July 2nd. Finally, Robert W. Baird restated an outperform rating and issued a $18.00 price objective on shares of R1 RCM in a research report on Tuesday, July 2nd. Ten research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Hold and an average target price of $16.02.

R1 RCM Trading Down 0.1 %

RCM traded down $0.02 on Thursday, hitting $14.11. 504,675 shares of the stock traded hands, compared to its average volume of 3,583,944. R1 RCM has a 52 week low of $8.87 and a 52 week high of $18.52. The business has a fifty day moving average price of $12.63 and a two-hundred day moving average price of $12.27. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.78.

R1 RCM (NASDAQ:RCM) last released its quarterly earnings data on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03). The company had revenue of $603.90 million during the quarter, compared to the consensus estimate of $612.88 million. R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The company’s quarterly revenue was up 10.7% on a year-over-year basis. On average, analysts expect that R1 RCM will post -0.2 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Privium Fund Management UK Ltd purchased a new stake in shares of R1 RCM during the 2nd quarter valued at approximately $502,000. CIBC Asset Management Inc purchased a new stake in shares of R1 RCM during the 2nd quarter valued at approximately $149,000. BW Gestao de Investimentos Ltda. lifted its stake in shares of R1 RCM by 14.9% during the 2nd quarter. BW Gestao de Investimentos Ltda. now owns 1,027,220 shares of the healthcare provider’s stock valued at $12,902,000 after buying an additional 133,324 shares in the last quarter. Pentwater Capital Management LP purchased a new stake in shares of R1 RCM during the 2nd quarter valued at approximately $2,512,000. Finally, Intact Investment Management Inc. purchased a new stake in R1 RCM in the 2nd quarter worth approximately $621,000. 61.10% of the stock is currently owned by hedge funds and other institutional investors.

R1 RCM Company Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.